Proprietary Name Evaluation Guidance Will Detail New FDA Review Process
Executive Summary
FDA expects to publish a draft guidance on "Evaluating Proprietary Names" in the next few months to explain its new procedures for evaluating proposed drug names in order to avoid medication errors.
You may also be interested in...
FDA Drug Name Policy "Discourages" New Brand Names For Old Ingredients
FDA's Office of Postmarketing Drug Risk Assessment is "discouraging" applications that would create a new brand name for an existing active ingredient.
FDA Drug Name Policy "Discourages" New Brand Names For Old Ingredients
FDA's Office of Postmarketing Drug Risk Assessment is "discouraging" applications that would create a new brand name for an existing active ingredient.
Off Label Drug Use Data To Be Required In Periodic Safety Updates - FDA
Pharmaceutical companies will be asked to provide postmarketing drug usage information in their periodic safety update reports, including use in off label indications, under a proposed FDA rule due out later this year.